Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 607 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Development Clear all
Completed Phase 3 Interventional

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00112554
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, laromustine, placebo
Drug · Other
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
24
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 30, 2026, 6:54 PM EDT
Completed No phase listed Observational

SPAIN Chest Wall Deformity Project (Pectus Repair)

NCT02098681
View directory record Official record
Conditions
Deformity of Chest Wall
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 30 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 30, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional

Cilengitide in Treating Patients With Acute Myeloid Leukemia

NCT00089388
View directory record Official record
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b)
Interventions
cilengitide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 30, 2026, 6:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes

NCT02213484
View directory record Official record
Conditions
Marfan Syndrome, Loeys-Dietz Syndrome, Thoracic Aortic Aneurysm and Dissection Syndromes, Ehlers-Danlos Type IV Syndrome, Turner Syndrome
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Days to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 30, 2026, 6:54 PM EDT
Not listed Phase 3 Interventional

Treatment of Children With Insufficient Secretion of Growth Hormone

NCT00271518
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
growth hormone (somatropin)
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
3 Years to 11 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 30, 2026, 6:54 PM EDT
Completed No phase listed Observational

Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

NCT02005198
View directory record Official record
Conditions
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
23 Years to 79 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 30, 2026, 6:54 PM EDT
Not listed Phase 3 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00454168
View directory record Official record
Conditions
Leukemia
Interventions
PR1 leukemia peptide vaccine, sargramostim, placebo
Biological · Other
Lead sponsor
The Vaccine Company
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 30, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 30, 2026, 6:54 PM EDT
Completed No phase listed Observational

Syndactyly Repair: Comparison of Skin Graft and No Skin Graft Techniques

NCT01416090
View directory record Official record
Conditions
Congenital Hand Deformities
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
6 Months to 6 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRI for Non-invasive Evaluation of Brain Stress

NCT01898650
View directory record Official record
Conditions
Craniosynostosis
Interventions
MR scan
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 18 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Bisphosphonate Treatment of Osteogenesis Imperfecta

NCT00063479
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Zoledronic Acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Wilmington, Delaware • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 30, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02029417
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, omacetaxine mepesuccinate, decitabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Genotropin Study Assessing Use of Injection Pen

NCT00965484
View directory record Official record
Conditions
Growth Hormone Deficiency, Idiopathic Short Stature
Interventions
New Genotropin Pen
Device
Lead sponsor
Pfizer
Industry
Eligibility
8 Years to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Greenwood Village, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2011 · Synced Oct 30, 2026, 6:54 PM EDT
Recruiting Phase 1 Interventional

Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

NCT06438471
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain, Degenerative Disc Disease, Spinal Stenosis, Spondylosis
Interventions
EC5026 oral tablet, Placebo oral tablet
Drug
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 6:54 PM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

NCT03638128
View directory record Official record
Conditions
Osteogenesis Imperfecta (OI)
Interventions
Denosumab, Alternative osteoporosis medications
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 30, 2026, 6:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of NeoPlex4 Assay and NeoPlex System

NCT01488721
View directory record Official record
Conditions
Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
1 Day to 7 Days
Enrollment
7,462 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Albany, New York • Nashville, Tennessee • Taylorsville, Utah
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

NCT00429364
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Losartan Potassium, Atenolol
Drug
Lead sponsor
Carelon Research
Other
Eligibility
6 Months to 25 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
24
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 30, 2026, 6:54 PM EDT
Terminated No phase listed Observational

MDR - Longevity IT Oblique and Offset Liners

NCT05980234
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Protrusio Acetabuli, Traumatic Arthritis, Slipped Capital Femoral Epiphyses, Fracture of the Pelvis, Diastrophic Variant, Osteoarthritis, Fused Hip
Interventions
Total Hip Arthroplasty with Longevity IT Oblique Liners, Total Hip Arthroplasty with Longevity IT Offset Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 30, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00268242
View directory record Official record
Conditions
Leukemia
Interventions
Gemcitabine Hydrochloride, Mitoxantrone Hydrochloride
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 30, 2026, 6:54 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Romosozumab, Bisphosphonate
Drug
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 30, 2026, 6:54 PM EDT
Withdrawn Phase 2 Interventional

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

NCT02846766
View directory record Official record
Conditions
Cancer
Interventions
Lenvatinib
Drug
Lead sponsor
Teresa Helsten, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
La Jolla, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 30, 2026, 6:54 PM EDT
Not listed Phase 2 Interventional

Growth Hormone Replacement Therapy for Retried Professional Football Players

NCT04121780
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Interventions
Growth Hormone, Placebo
Biological · Other
Lead sponsor
Center for Neurological Studies
Other
Eligibility
18 Years to 76 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

NCT00006019
View directory record Official record
Conditions
Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Prostate Cancer
Interventions
azacitidine, sodium phenylbutyrate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 30, 2026, 6:54 PM EDT